The Claim
Rapamycin extends median lifespan by 9% in male and 14% in female genetically heterogeneous mice when treatment is initiated at 600 days of age (late life), representing the first demonstrated pharmacological extension of mammalian lifespan.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called rapamycin helped mice live longer - males lived about 9% longer and females lived about 14% longer when they started taking the drug in late adulthood.
See the scientific wording
Rapamycin extends median lifespan by 9% in male and 14% in female genetically heterogeneous mice when treatment is initiated at 600 days of age (late life), representing the first demonstrated pharmacological extension of mammalian lifespan.
What the research says
2 studiesStudy: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
The study fed rapamycin to mice starting at 600 days old and found it extended lifespan by 14% for females and 9% for males - exactly matching the claim. This was done in genetically heterogeneous mice and is described as the first pharmacological extension of mammalian lifespan.
Related videos
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 2 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.